NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01130025,Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer,https://clinicaltrials.gov/study/NCT01130025,,COMPLETED,The purpose of this study is to assess the efficacy and safety of Innohep® in preventing the recurrence of VTE in patients with active cancer who have had an acute VTE episode.,NO,Venous Thromboembolism,DRUG: Warfarin|DRUG: Innohep®,"Composite end-point represented by the time in days from randomisation to the first occurrence of VTE, * Symptomatic non-fatal DVTs.
* Symptomatic non-fatal PEs.
* Fatal PE.
* Incidental proximal DVT (popliteal vein or higher).
* Incidental proximal PE (segmental arteries or larger)., 6 months","Time in days from randomisation to the first occurrence of VTE., * The 5 individual components of the composite primary efficacy endpoint.
* A composite endpoint of symptomatic DVT and/or PE, including fatal PE.

Safety endpoints will consist of bleeding and overall mortality, 6 months",,LEO Pharma,,ALL,"ADULT, OLDER_ADULT",PHASE3,900,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,IN 0901 INT|2009-018141-20,2010-08,2014-04,2014-05,2010-05-25,,2025-03-25,"Diamond Health Care Centre, Vancouver, British Columbia, BC V5Z 1M9, Canada",
